Image

Avalanche Phenomenon During Airways Opening in Acute Respiratory Distress Syndrome

Avalanche Phenomenon During Airways Opening in Acute Respiratory Distress Syndrome

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Acute respiratory distress syndrome accounts for 23% of mechanically ventilated patients and is associated with high mortality rate. Although life-saving, mechanical ventilation may worsen lung injury through two main mechanisms: lung overdistension and atelectrauma. Indeed, the cyclic opening and closure of airways during tidal ventilation may cause lung and bronchial injuries as suggested by animal models and autopsy findings. Complete airways closure has recently been described in 40% of patients with acute respiratory distress syndrome, and setting positive end-expiratory pressure above the airway opening pressure may limit atelectrauma. However, animal and mathematical models suggest that above the airway opening pressure, more distal airways open unevenly according to their own opening pressure, resulting in an "avalanche"-like phenomenon during lung inflation. This phenomenon has never been described in humans. A better understanding of the opening of airways in acute respiratory distress syndrome may help to limit ventilation-induced lung injury and to improve outcomes.

Eligibility

Inclusion Criteria:

  • Age ≥ 18
  • Moderate-to-severe acute respiratory distress syndrome within the first 72 hours after meeting the Berlin definition criteria:
  • Within 1 week of a known clinical insult or new or worsening respiratory symptoms;
  • Bilateral opacities (not fully explained by effusions, lobar/lung collapse, or nodules);
  • Respiratory failure not fully explained by cardiac failure or fluid overload;
  • PaO2/FiO2 ≤ 200 mmHg with positive end-expiratory pressure ≥ 5 cmH2O.
  • Absence of spontaneous breathing efforts
  • Consent to participate to the study from the patient and/or its surrogate

Exclusion Criteria:

  • Pneumothorax
  • Broncho-pleural fistula
  • Tracheostomy
  • Hemodynamic instability
  • Severe hypoxemia
  • Suspected of proven intracranial hypertension
  • Chronic obstructive lung disease
  • Pacemaker or defibrillator
  • Decision to withhold of withdraw life-sustaining measures
  • Under protection

Study details
    Acute Respiratory Distress Syndrome

NCT05224323

Poitiers University Hospital

30 January 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.